Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. on behalf of investors who purchased its common stock during the February 8, 2024 IPO, with a lead plaintiff deadline set for February 7, 2025 [1]. Group 1: Allegations Against Kyverna - The lawsuit alleges that Kyverna's prospectus and registration statements contained materially false and misleading statements regarding the company's business, operations, and prospects [2]. - Specifically, it is claimed that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors in Kyverna have until February 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will act on behalf of all class members and typically is the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions of dollars for victims of fraud and corporate misconduct [5]. - The firm encourages Kyverna investors who have suffered significant losses to contact them for more information [4].
KYTX Deadline Approaching on February 7, 2025: Kessler Topaz Meltzer & Check, LLP Reminds Kyverna Therapeutics, Inc. (KYTX) Investors of Class Action Lawsuit Deadline